Case-Based Roundtable Meetings Spotlight: April 2 2022

During a Targeted Oncology case-based roundtable event, Hetty Carraway, MD, MBA, discussed risk factors for tumor lysis syndrome and the use of prophylactic agents.

During a Targeted Oncology case-based roundtable event, Brian Rini, MD, discussed the choice of treatment options including dual immunotherapy and tyrosine kinase inhibitors plus immunotherapy for a patient with stage IV clear cell renal cell carcinoma.

During a Targeted Oncology case-based event, Lindsey Roeker, MD, discussed risk assessment and frontline therapy for a patient diagnosed with chronic lymphocytic leukemia.

During a Targeted Oncology case-based roundtable event, Jonathan Wesley Riess, MD, MS, discussed the case of a 72-year-old patient with non–small cell lung cancer with high PD-L1 expression.

During a Targeted Oncology case-based roundtable event, Victor Yazbeck, MD, MS, discussed the data from recent clinical trials of tafasitamab/lenalidomide, polatuzumab vedotin, and loncastuximab tesirine for patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Srdan Verstovsek, MD, PhD, discussed the use of JAK inhibitors for patients with higher-risk myelofibrosis.

During a Targeted Oncology case-based roundtable event, Thomas C. Krivak, MD, discussed the results of studies of PARP inhibition for patients with advanced ovarian cancer.

During a case-based roundtable event, Estelamari Rodriguez, MD, MPH, discussed the case of a patient who had lung cancer with 3 brain metastases and a RET fusion.

During a case-based roundtable event, Dan Vogl, MD, MSCE, discussed possible targeted therapies for a patient with relapsed/refractory multiple myeloma who had previously received several combination therapies.

During a case-based roundtable event, Kevin Kalinsky, MD, MS, discussed clinical typing of patients with breast cancer and the results of trials of therapies for patients with HR-positive, HER2-negative breast cancer.